日本分子靶向药物和免疫检查点抑制剂治疗不可切除或复发/转移性口腔癌的疗效和安全性

IF 3.4 3区 医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE Journal of Dental Sciences Pub Date : 2024-07-01 DOI:10.1016/j.jds.2023.11.024
Mitsunobu Otsuru , Nobuhiro Yamakawa , Tadaaki Kirita , Shin-ichi Yamada , Hiroshi Kurita , Takuma Kugimoto , Hiroyuki Harada , Takumi Hasegawa , Masaya Akashi , Akinori Takeshita , Narikazu Uzawa , Masahiro Umeda , Souichi Yanamoto , Tomohiro Yamada
{"title":"日本分子靶向药物和免疫检查点抑制剂治疗不可切除或复发/转移性口腔癌的疗效和安全性","authors":"Mitsunobu Otsuru ,&nbsp;Nobuhiro Yamakawa ,&nbsp;Tadaaki Kirita ,&nbsp;Shin-ichi Yamada ,&nbsp;Hiroshi Kurita ,&nbsp;Takuma Kugimoto ,&nbsp;Hiroyuki Harada ,&nbsp;Takumi Hasegawa ,&nbsp;Masaya Akashi ,&nbsp;Akinori Takeshita ,&nbsp;Narikazu Uzawa ,&nbsp;Masahiro Umeda ,&nbsp;Souichi Yanamoto ,&nbsp;Tomohiro Yamada","doi":"10.1016/j.jds.2023.11.024","DOIUrl":null,"url":null,"abstract":"<div><h3>Background/purpose</h3><p>For unresectable recurrent/metastatic head and neck cancer, pembrolizumab alone or pembrolizumab combined with cisplatin and 5-fluorouracil is the first-line therapy, depending on the PD-L1 combined positive score (CPS). However, this is based on clinical studies of head and neck cancer, and few similar studies have been conducted on oral cancer alone. This study aimed to investigate the current status of pharmacotherapy for unresectable, recurrent, or metastatic oral cancer.</p></div><div><h3>Materials and methods</h3><p>Patients with unresectable or recurrent/metastatic oral cancer who received cetuximab, nivolumab, or pembrolizumab as first-line treatment were reviewed. Overall survival (OS), progression-free survival (PFS), PFS 2 (PFS2), overall response rate (ORR), disease control rate (DCR), and immune-related adverse events were obtained from medical records.</p></div><div><h3>Results</h3><p>A total of 155 patients were enrolled from six hospitals. The ORR in the nivolumab, pembrolizumab, and cetuximab groups was 17.2 %, 4.2 %, and 21.6 %, respectively, and the DCR was 37.9 %, 41.7 %, and 58.8 %, respectively. Median OS in nivolumab, pembrolizumab, and cetuximab groups was 10.3, 9.5, and 11.1 months, respectively. No significant differences were observed in survival among the three groups. The small number of cases and the retrospective nature of the study precluded the determination of the more effective first-line treatment among the three drugs.</p></div><div><h3>Conclusion</h3><p>The current statuses of nivolumab, pembrolizumab, and cetuximab in unresectable recurrent metastatic oral cancer was reported.</p></div>","PeriodicalId":15583,"journal":{"name":"Journal of Dental Sciences","volume":"19 3","pages":"Pages 1628-1637"},"PeriodicalIF":3.4000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1991790223003914/pdfft?md5=b2aa8be6a8163bce184b105c0c62a8fe&pid=1-s2.0-S1991790223003914-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Efficacy and safety of molecularly targeted agents and immune checkpoint inhibitors for unresectable or recurrent/metastatic oral cancer in Japan\",\"authors\":\"Mitsunobu Otsuru ,&nbsp;Nobuhiro Yamakawa ,&nbsp;Tadaaki Kirita ,&nbsp;Shin-ichi Yamada ,&nbsp;Hiroshi Kurita ,&nbsp;Takuma Kugimoto ,&nbsp;Hiroyuki Harada ,&nbsp;Takumi Hasegawa ,&nbsp;Masaya Akashi ,&nbsp;Akinori Takeshita ,&nbsp;Narikazu Uzawa ,&nbsp;Masahiro Umeda ,&nbsp;Souichi Yanamoto ,&nbsp;Tomohiro Yamada\",\"doi\":\"10.1016/j.jds.2023.11.024\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background/purpose</h3><p>For unresectable recurrent/metastatic head and neck cancer, pembrolizumab alone or pembrolizumab combined with cisplatin and 5-fluorouracil is the first-line therapy, depending on the PD-L1 combined positive score (CPS). However, this is based on clinical studies of head and neck cancer, and few similar studies have been conducted on oral cancer alone. This study aimed to investigate the current status of pharmacotherapy for unresectable, recurrent, or metastatic oral cancer.</p></div><div><h3>Materials and methods</h3><p>Patients with unresectable or recurrent/metastatic oral cancer who received cetuximab, nivolumab, or pembrolizumab as first-line treatment were reviewed. Overall survival (OS), progression-free survival (PFS), PFS 2 (PFS2), overall response rate (ORR), disease control rate (DCR), and immune-related adverse events were obtained from medical records.</p></div><div><h3>Results</h3><p>A total of 155 patients were enrolled from six hospitals. The ORR in the nivolumab, pembrolizumab, and cetuximab groups was 17.2 %, 4.2 %, and 21.6 %, respectively, and the DCR was 37.9 %, 41.7 %, and 58.8 %, respectively. Median OS in nivolumab, pembrolizumab, and cetuximab groups was 10.3, 9.5, and 11.1 months, respectively. No significant differences were observed in survival among the three groups. The small number of cases and the retrospective nature of the study precluded the determination of the more effective first-line treatment among the three drugs.</p></div><div><h3>Conclusion</h3><p>The current statuses of nivolumab, pembrolizumab, and cetuximab in unresectable recurrent metastatic oral cancer was reported.</p></div>\",\"PeriodicalId\":15583,\"journal\":{\"name\":\"Journal of Dental Sciences\",\"volume\":\"19 3\",\"pages\":\"Pages 1628-1637\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S1991790223003914/pdfft?md5=b2aa8be6a8163bce184b105c0c62a8fe&pid=1-s2.0-S1991790223003914-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Dental Sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1991790223003914\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"DENTISTRY, ORAL SURGERY & MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Dental Sciences","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1991790223003914","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}
引用次数: 0

摘要

背景/目的对于无法切除的复发性/转移性头颈部癌症,根据 PD-L1 联合阳性评分(CPS),pembrolizumab 单药或 pembrolizumab 联合顺铂和 5-氟尿嘧啶是一线疗法。然而,这是基于头颈部癌症的临床研究,很少有类似的研究单独针对口腔癌。本研究旨在调查不可切除、复发或转移性口腔癌的药物治疗现状。材料与方法回顾了接受西妥昔单抗、尼维单抗或彭博利珠单抗作为一线治疗的不可切除或复发/转移性口腔癌患者。从病历中获取了总生存期(OS)、无进展生存期(PFS)、无进展生存期2(PFS2)、总反应率(ORR)、疾病控制率(DCR)以及免疫相关不良事件。nivolumab组、pembrolizumab组和西妥昔单抗组的ORR分别为17.2%、4.2%和21.6%,DCR分别为37.9%、41.7%和58.8%。nivolumab、pembrolizumab和西妥昔单抗组的中位生存期分别为10.3个月、9.5个月和11.1个月。三组患者的生存期无明显差异。由于病例数较少,且该研究具有回顾性,因此无法确定三种药物中哪种一线治疗更有效。结论 本研究报告了尼妥珠单抗、彭博利珠单抗和西妥昔单抗治疗不可切除的复发性转移性口腔癌的现状。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Efficacy and safety of molecularly targeted agents and immune checkpoint inhibitors for unresectable or recurrent/metastatic oral cancer in Japan

Background/purpose

For unresectable recurrent/metastatic head and neck cancer, pembrolizumab alone or pembrolizumab combined with cisplatin and 5-fluorouracil is the first-line therapy, depending on the PD-L1 combined positive score (CPS). However, this is based on clinical studies of head and neck cancer, and few similar studies have been conducted on oral cancer alone. This study aimed to investigate the current status of pharmacotherapy for unresectable, recurrent, or metastatic oral cancer.

Materials and methods

Patients with unresectable or recurrent/metastatic oral cancer who received cetuximab, nivolumab, or pembrolizumab as first-line treatment were reviewed. Overall survival (OS), progression-free survival (PFS), PFS 2 (PFS2), overall response rate (ORR), disease control rate (DCR), and immune-related adverse events were obtained from medical records.

Results

A total of 155 patients were enrolled from six hospitals. The ORR in the nivolumab, pembrolizumab, and cetuximab groups was 17.2 %, 4.2 %, and 21.6 %, respectively, and the DCR was 37.9 %, 41.7 %, and 58.8 %, respectively. Median OS in nivolumab, pembrolizumab, and cetuximab groups was 10.3, 9.5, and 11.1 months, respectively. No significant differences were observed in survival among the three groups. The small number of cases and the retrospective nature of the study precluded the determination of the more effective first-line treatment among the three drugs.

Conclusion

The current statuses of nivolumab, pembrolizumab, and cetuximab in unresectable recurrent metastatic oral cancer was reported.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Dental Sciences
Journal of Dental Sciences 医学-牙科与口腔外科
CiteScore
5.10
自引率
14.30%
发文量
348
审稿时长
6 days
期刊介绍: he Journal of Dental Sciences (JDS), published quarterly, is the official and open access publication of the Association for Dental Sciences of the Republic of China (ADS-ROC). The precedent journal of the JDS is the Chinese Dental Journal (CDJ) which had already been covered by MEDLINE in 1988. As the CDJ continued to prove its importance in the region, the ADS-ROC decided to move to the international community by publishing an English journal. Hence, the birth of the JDS in 2006. The JDS is indexed in the SCI Expanded since 2008. It is also indexed in Scopus, and EMCare, ScienceDirect, SIIC Data Bases. The topics covered by the JDS include all fields of basic and clinical dentistry. Some manuscripts focusing on the study of certain endemic diseases such as dental caries and periodontal diseases in particular regions of any country as well as oral pre-cancers, oral cancers, and oral submucous fibrosis related to betel nut chewing habit are also considered for publication. Besides, the JDS also publishes articles about the efficacy of a new treatment modality on oral verrucous hyperplasia or early oral squamous cell carcinoma.
期刊最新文献
Editorial Board New model of tele-healthcare for consultation, diagnosis, and treatment of a cicatricial pemphigoid case using mobile phones for communication among the patient, the clinic dentist, and the oral pathology specialist Traumatic neuroma of the lower lip The dental teleradiology in the National Taiwan University Hospital system Maxillary posterior implant as a surveyed crown for implant-assisted removable partial denture: A case report with 10-year follow-up
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1